Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Series A Common Stock, par value $0.0001 per share
-
Shares outstanding
-
31.3M
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
17.5M
-
Shares change
-
-2.17M
-
Total reported value, excl. options
-
$78.8M
-
Value change
-
-$8.86M
-
Put/Call ratio
-
4.52
-
Number of buys
-
27
-
Number of sells
-
-33
-
Price
-
$4.50
Significant Holders of Sagimet Biosciences Inc. - Series A Common Stock, par value $0.0001 per share (SGMT) as of Q4 2024
84 filings reported holding SGMT - Sagimet Biosciences Inc. - Series A Common Stock, par value $0.0001 per share as of Q4 2024.
Sagimet Biosciences Inc. - Series A Common Stock, par value $0.0001 per share (SGMT) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.5M shares
of 31.3M outstanding shares and own 55.95% of the company stock.
Largest 10 shareholders include Point72 Asset Management, L.P. (2.32M shares), NEA Management Company, LLC (2M shares), Blue Owl Capital Holdings LP (1.32M shares), Alyeska Investment Group, L.P. (1.29M shares), VANGUARD GROUP INC (1.13M shares), BlackRock, Inc. (979K shares), BAKER BROS. ADVISORS LP (953K shares), Rock Springs Capital Management LP (788K shares), CITADEL ADVISORS LLC (745K shares), and HHLR ADVISORS, LTD. (725K shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.